February 13, 2019
Astellas Pharma/Pfizer’s cancer drug Xtandi (enzalutamide) significantly extended radiographic progression-free survival (rPFS) in metastatic hormone-sensitive prostate cancer (mHSPC), with the drug plus androgen deprivation therapy (ADT) slashing the risk of radiographic progression or death by 61% versus ADT alone. The...read more